Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Nephrology
Volume 2018 (2018), Article ID 1727986, 4 pages
https://doi.org/10.1155/2018/1727986
Case Report

De Novo Atypical Haemolytic Uremic Syndrome after Kidney Transplantation

1Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
2Division of Abdominal Surgery and Transplantation, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
3Division of Pathology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
4Division of Human Genetics, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
5Center of Human Genetics, Institut de Pathologie et de Génétique, Gosselies, Belgium

Correspondence should be addressed to Nada Kanaan; eb.niavuolcu@naanak.adan

Received 15 November 2017; Revised 23 January 2018; Accepted 14 February 2018; Published 14 March 2018

Academic Editor: Sophia Lionaki

Copyright © 2018 Arnaud Devresse et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Brocklebank, K. M. Wood, and D. Kavanagh, “Thrombotic microangiopathy and the kidney,” Clinical Journal of the American Society of Nephrology, 2017. View at Google Scholar
  2. J. Zuber, M. Le Quintrec, H. Morris, V. Frémeaux-Bacchi, C. Loirat, and C. Legendre, “Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation,” Transplantation Reviews, vol. 27, no. 4, pp. 117–125, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. M. le Quintrec, A. Lionet, N. Kamar et al., “Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation,” American Journal of Transplantation, vol. 8, no. 8, pp. 1694–1701, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. S. B. Bauer, “The Hinman Syndrome,” The Journal of Urology, vol. 197, no. 2, pp. S132–S133, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Verbiest, J. Pirenne, and D. Dierickx, “De novo thrombotic microangiopathy after non-renal solid organ transplantation,” Blood Reviews, vol. 28, no. 6, pp. 269–279, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Ponticelli and G. Banfi, “Thrombotic microangiopathy after kidney transplantation,” Transplant International, vol. 19, no. 10, pp. 789–794, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. A. Satoskar, R. Pelletier, P. Adams et al., “De novo thrombotic microangiopathy in renal allograft biopsies—role of antibody-mediated rejection,” American Journal of Transplantation, vol. 10, no. 8, pp. 1804–1811, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Noris and G. Remuzzi, “Atypical hemolytic-uremic syndrome,” The New England Journal of Medicine, vol. 361, no. 17, pp. 1676–1687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Okumi and K. Tanabe, “Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation,” Nephrology, vol. 21, pp. 9–13, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Fakhouri, J. Zuber, V. Frémeaux-Bacchi, and C. Loirat, “Haemolytic uraemic syndrome,” The Lancet, vol. 390, no. 10095, pp. 681–696, 2017. View at Google Scholar
  11. C. M. Legendre, C. Licht, P. Muus et al., “Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome,” The New England Journal of Medicine, vol. 368, no. 23, pp. 2169–2181, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Kumar, Z. Stewart, A. Reed et al., “Successful prophylactic use of eculizumab in ahus kidney transplant patients: a report of 9 cases,” American Journal of Transplantation, vol. 16, supplement 3, 2016. View at Google Scholar
  13. F. Bu, N. Borsa, A. Gianluigi, and R. J. H. Smith, “Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects,” Clinical and Developmental Immunology, vol. 2012, Article ID 370426, 9 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Caprioli, M. Noris, S. Brioschi et al., “Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome,” Blood, vol. 108, no. 4, pp. 1267–1279, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Kavanagh, A. Richards, and J. Atkinson, “Complement regulatory genes and hemolytic uremic syndromes,” Annual Review of Medicine, vol. 59, pp. 293–309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. T. H. Goodship, H. T. Cook, F. Fakhouri et al., “Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: improving Global Outcomes" (KDIGO) Controversies Conference,” Kidney International, vol. 99, no. 3, pp. 539–551, 2017. View at Google Scholar
  17. K. L. Wijnsma, C. Duineveld, E. B. Volokhina, L. P. van den Heuvel, N. C. van de Kar, and J. F. Wetzels, “Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome,” Nephrology Dialysis Transplantation , 2017. View at Publisher · View at Google Scholar
  18. C. Duineveld, J. C. Verhave, S. P. Berger, N. C. A. J. van de Kar, and J. F. M. Wetzels, “Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series,” American Journal of Kidney Diseases, vol. 70, no. 6, pp. 770–777, 2017. View at Google Scholar
  19. M. Noris, P. Ruggenenti, and G. Remuzzi, “Kidney transplantation in patients with atypical hemolytic uremic syndrome: a therapeutic dilemma (or not)?” American Journal of Kidney Diseases, vol. 70, no. 6, pp. 754–757, 2017. View at Publisher · View at Google Scholar